olaparib,abiraterone
astrazeneca,merck
['abira', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'olaparib', 'propel', 'abiraterone']
excellent propel trial : abiraterone (abi) + olaparib(ola) vs abi and 1l pbo in patients with mcrpc, results were abi + wave prolonged os by &gt; 7 m versus (abi+pbo) and the median os of &gt; 42 m is the longest median reported to date in a phase 3 trial in 1 l #mcrpc. #asco #gu23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.